MapLight director awarded RSUs and stock options
MapLight Therapeutics director Timothy John Garnett received new equity awards as part of non-employee director compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MapLight Therapeutics director Timothy John Garnett received new equity awards as part of non-employee director compensation. He was granted 3,932 restricted stock units, each representing one share of voting common stock, and a stock option for 14,902 shares at an exercise price of $28.64 per share.
Both the RSUs and the option vest on the earlier of June 23, 2027 or the company’s next annual stockholder meeting, subject to his Continuous Service under the 2025 Equity Incentive Plan. Following these awards, he holds 53,457 shares directly and 14,124 shares indirectly through the Timothy J Garnett Revocable Trust, where he has voting and dispositive power.
Insider Trade Summary
Grant/Award: 18,834 shares
Grant/Award
3 txns
Insider
Garnett Timothy John
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 14,902 | $0.00 | $0.00 |
| Grant/Award | Voting Common Stock | 3,932 | $0.00 | $0.00 |
| holding | Voting Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 14,902 contracts (Direct);
Voting Common Stock — 53,457 shares (Direct);
Voting Common Stock — 14,124 shares (Indirect, See footnote)
Footnotes (4)
- F1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
- F2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
- F3. The shares are held by the Timothy J Garnett Revocable Trust Dated U/A 09/22/2021, of which the Reporting Person is the sole trustee and has voting and dispositive power.
- F4. Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.
Key Figures
RSU grant size: 3,932 units
Stock option grant: 14,902 shares
Option exercise price: $28.64/share
+4 more
7 metrics
RSU grant size
3,932 units
Restricted stock units granted June 23, 2026
Stock option grant
14,902 shares
Option to buy voting common stock granted June 23, 2026
Option exercise price
$28.64/share
Stock option exercise price under 2025 Equity Incentive Plan
Option expiration
June 22, 2036
Expiration date of 14,902-share stock option
Direct holdings after grant
53,457 shares
Voting common stock held directly after transactions
Indirect holdings via trust
14,124 shares
Voting common stock held by Timothy J Garnett Revocable Trust
Vesting trigger date
June 23, 2027
Latest vesting date for RSUs and stock option, or earlier annual meeting
Key Terms
restricted stock units ("RSUs"), 2025 Equity Incentive Plan, Continuous Service, non-employee director compensation policy, +2 more
6 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2025 Equity Incentive Plan financial
"granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan")"
Continuous Service financial
"subject to the Continuous Service (as defined in the Plan) of the Reporting Person"
non-employee director compensation policy financial
"This grant was made pursuant to the Issuer's non-employee director compensation policy."
stock option financial
"Represents a stock option granted pursuant to the Plan."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
voting and dispositive power financial
"of which the Reporting Person is the sole trustee and has voting and dispositive power."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did MapLight Therapeutics (MPLT) report for Timothy John Garnett?
MapLight Therapeutics reported that director Timothy John Garnett received 3,932 restricted stock units and a stock option for 14,902 shares. These awards were granted at no cash cost as part of the company’s non-employee director compensation policy under its 2025 Equity Incentive Plan.
What are the vesting terms for Timothy John Garnett’s new MPLT restricted stock units?
The 3,932 restricted stock units granted to Timothy John Garnett vest on the earlier of June 23, 2027 or the date of MapLight Therapeutics’ next annual stockholder meeting. Vesting is conditioned on his Continuous Service, as defined in the company’s 2025 Equity Incentive Plan.
What are the key terms of Timothy John Garnett’s new MPLT stock option grant?
Garnett’s stock option covers 14,902 shares of MapLight Therapeutics voting common stock at an exercise price of $28.64 per share. The option vests on the earlier of June 23, 2027 or the next annual stockholder meeting and expires on June 22, 2036, subject to Continuous Service.
Are Timothy John Garnett’s new MPLT equity awards open-market purchases or compensation grants?
The reported transactions are compensation-related grants, not open-market purchases. Both the 3,932 restricted stock units and the option for 14,902 shares were awarded at a price of $0.00 per unit under MapLight Therapeutics’ non-employee director compensation policy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
